| Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.PMID 40996773 · JAMA Oncol |
2025-Nov-01 |
2 | 5 | 5 | 10 |
提取完成 |
| Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.PMID 40641008 · J Clin Pharmacol |
2025-Nov |
1 | 2 | 2 | 4 |
质量警告 |
| Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.PMID 40680993 · Ann Oncol |
2025-Nov |
1 | 1 | 1 | 2 |
提取完成 |
| Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.PMID 40899645 · Cancer Commun (Lond) |
2025-Nov |
4 | 24 | 22 | 38 |
部分完成 |
| Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.PMID 40913104 · Leukemia |
2025-Nov |
1 | 3 | 3 | 5 |
质量警告 |
| Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.PMID 40976711 · Cancer Sci |
2025-Nov |
2 | 3 | 3 | 6 |
提取完成 |
| Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.PMID 41167084 · ESMO Open |
2025-Nov |
3 | 8 | 8 | 23 |
质量警告 |
| Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.PMID 41184595 · Target Oncol |
2025-Nov |
1 | 3 | 3 | 9 |
提取完成 |
| Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.PMID 41320342 · ESMO Open |
2025-Nov |
3 | 5 | 5 | 9 |
质量警告 |
| Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.PMID 41173494 · J Immunother Cancer |
2025-Oct-31 |
1 | 3 | 3 | 5 |
质量警告 |
| Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.PMID 40737596 · Blood |
2025-Oct-30 |
2 | 8 | 8 | 24 |
提取完成 |
| Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.PMID 41052510 · Lancet |
2025-Oct-25 |
2 | 6 | 6 | 11 |
质量警告 |
| Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.PMID 40902136 · J Clin Oncol |
2025-Oct-10 |
2 | 4 | 4 | 8 |
提取完成 |
| Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).PMID 41052983 · Blood Cancer J |
2025-Oct-06 |
3 | 3 | 3 | 6 |
提取完成 |
| Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.PMID 41032300 · JAMA Netw Open |
2025-Oct-01 |
1 | 3 | 3 | 6 |
提取完成 |
| Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.PMID 40613748 · CPT Pharmacometrics Syst Pharmacol |
2025-Oct |
1 | 2 | 1 | 5 |
部分完成 |
| Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.PMID 40750932 · Nat Med |
2025-Oct |
6 | 27 | 27 | 54 |
提取完成 |
| COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.PMID 41139117 · ESMO Open |
2025-Oct |
2 | 3 | 2 | 4 |
部分完成 |
| Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.PMID 40523203 · J Clin Oncol |
2025-Sep-20 |
1 | 1 | 0 | 0 |
提取失败 |
| Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.PMID 40198878 · Blood |
2025-Sep-11 |
2 | 2 | 2 | 6 |
提取完成 |
| Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.PMID 40454705 · J Clin Oncol |
2025-Sep-10 |
1 | 1 | 1 | 3 |
提取完成 |
| FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.PMID 40569606 · Clin Cancer Res |
2025-Sep-02 |
1 | 2 | 2 | 4 |
提取完成 |
| Covered versus uncovered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting: randomized clinical trial (CReST2).PMID 40966674 · Br J Surg |
2025-Sep-02 |
1 | 2 | 2 | 3 |
质量警告 |
| Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial.PMID 40971156 · JAMA Netw Open |
2025-Sep-02 |
1 | 3 | 3 | 6 |
提取完成 |
| Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.PMID 40515508 · Pediatr Blood Cancer |
2025-Sep |
2 | 2 | 2 | 10 |
提取完成 |
| Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.PMID 40958065 · Target Oncol |
2025-Sep |
1 | 4 | 4 | 16 |
提取完成 |
| Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.PMID 40866342 · Signal Transduct Target Ther |
2025-Aug-28 |
2 | 2 | 2 | 4 |
质量警告 |
| The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.PMID 40851062 · BMC Cancer |
2025-Aug-25 |
3 | 11 | 11 | 19 |
质量警告 |
| Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.PMID 40623279 · J Clin Oncol |
2025-Aug-20 |
1 | 6 | 6 | 8 |
质量警告 |
| Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.PMID 40127397 · Blood |
2025-Aug-07 |
1 | 2 | 2 | 5 |
质量警告 |